Performance Supplements Cause Reversible Gynecomastia and Low Testosterone in Men
Background
Many individuals use commercial performance-enhancing supplements to improve physical capabilities and appearance. While some supplements are benign, others contain undisclosed or unregulated ingredients that can have significant adverse effects on the body's endocrine system. Gynecomastia (the enlargement of male breast tissue) and hypogonadism (a condition where the body produces insufficient testosterone) are serious potential side effects. This case report addresses the specific knowledge gap regarding the reversibility of these conditions upon cessation of such supplements.
Results
Upon presentation, the patient exhibited classic symptoms of hypogonadism, with serum total testosterone levels significantly suppressed from a baseline of 20 nmol/L to 7 nmol/L, representing a 65% reduction. Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) were also markedly suppressed, indicating central hypothalamic-pituitary-gonadal axis dysfunction. Concurrently, the patient developed bilateral gynecomastia, with palpable breast tissue measuring approximately 3 cm in diameter. After discontinuing the performance-enhancing supplements, a remarkable recovery was observed. Within 3 months, his total testosterone levels rebounded to 18 nmol/L, a 90% recovery towards his baseline, and LH/FSH levels normalized. The gynecomastia also showed significant regression, with a 70% reduction in size over 6 months. The most significant finding was the complete reversal of hypogonadism and substantial regression of gynecomastia within 3 to 6 months following the cessation of the commercial performance-enhancing supplements.
Why It Matters
This case report highlights the critical public health risk posed by unregulated commercial performance-enhancing supplements, which often contain undisclosed anabolic or pro-hormonal agents. The reversibility of the endocrine dysfunction underscores the importance of early identification and intervention. This finding could lead to improved clinical guidelines for managing patients presenting with gynecomastia and hypogonadism, emphasizing a thorough history of supplement use. Further research, potentially involving larger cohort studies or analytical testing of seized supplements, is needed to identify specific causative agents and inform regulatory actions.